Program
ifebemtinib
Also written as “IN10018”, “BI 853520” and “IN10018 in combination with PLD”.
Its studies are mostly in Ovarian Neoplasms · Neoplasms · Pancreatic Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 5 companies.
Drug pageIfebemtinib: every studyMany companies study it; this page follows only the 16 they lead. All 16 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InxMed (Shanghai) | 117 open or running | phase 3since Aug 29, 2025 | Sep 26, 2019 | Mar 24, 2027phase 2 · NCT06014528 |
| Boehringer Ingelheimits history only | 20 open or running | phase 1since Apr 7, 2011 | Apr 7, 2011 | none ahead |
| Hangzhou Hanx Biopharmaceuticalsits history only | 11 open or running | phase 2since Nov 25, 2024 | Nov 25, 2024 | Dec 31, 2027phase 2 · NCT06708663 |
| InventisBioits history only | 11 open or running | phase 2since May 13, 2022 | May 13, 2022 | Dec 31, 2027phase 2 · NCT05379946 |
| Shanghai Jeyou Pharmaceuticalits history only | 11 open or running | phase 3since Sep 13, 2026 | Sep 13, 2026 | Apr 2029phase 3 · NCT07833202 |
- Named in fosun pharma’s own pipeline as
IN10018 (FAK)
, phase 3, as of Sep 21, 2026 (source).
Also a collaborator on its studies: Ranok Therapuetics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of InxMed (Shanghai) only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 26, 2019First study: phase 1 study in MelanomaFirst studyNCT04109456 · 51 enrolled · United States, Australia
- Mar 29, 2022Phase 1 study in Stomach NeoplasmsNCT05327231 · 33 enrolled · China
- Sep 15, 2022Phase 2 study in Platinum-resistant Ovarian CancerNCT05551507 · 150 enrolled · China
- Jan 19, 2023Named ifebemtinibINNProposed as its International Nonproprietary Name in WHO's List 128 · before, IN10018, BI 853520
- Mar 28, 20232 phase 2 studiesNCT05827796, NCT05830539
- Jul 13, 2023Phase 2 study in Solid TumorNCT05982522
- Aug 8, 20232 phase 2 studiesNCT05994131, NCT06014528
- Sep 1, 2023Phase 2 study in Small Cell Lung Cancer Extensive StageNCT06030258 · 120 enrolled · China
- Aug 29, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07174908 · 400 planned · China
- Feb 13, 2026Phase 2 study in Solid Tumor CancerNCT07441174 · 92 planned · China
Ahead
- Mar 24, 2027Primary completion: phase 2 study in Ovarian Cancer RecurrentNCT06014528
- Sep 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07174908
- Feb 28, 2031Primary completion: phase 2 study in Solid Tumor CancerNCT07441174
TargetBeta
“An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) ”NCIt, by rule
“Focal adhesion kinase 1 inhibitor”ChEMBL 37, by rule
Other programs on PTK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
Studies
All 11 InxMed (Shanghai) leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07441174Solid Tumor Cancer · China | 2 | Recruiting | Feb 28, 2031 | 92 |
| NCT07174908Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Sep 2028 | 400 |
| NCT06030258Small Cell Lung Cancer Extensive Stage · China | 2 | Active, not recruiting | Nov 20, 2025 | 120 |
| NCT06014528Ovarian Cancer Recurrent · China | 2 | Active, not recruiting | Mar 24, 2027 | 168 |
| NCT05994131NSCLC · China | 2 | Active, not recruiting | Sep 20, 2025 | 110 |
| NCT05982522Solid Tumor | 2 | Withdrawn | Dec 31, 2026 | 0 |
| NCT05830539Locally Advanced or Metastatic Solid Tumors · China | 2 | Completed | Aug 31, 2024 | 68 |
| NCT05827796Pancreatic Neoplasms · China | 2 | Active, not recruiting | Oct 11, 2025 | 70 |
| NCT05551507Platinum-resistant Ovarian Cancer · China | 2 | Active, not recruiting | May 11, 2026 | 150 |
| NCT05327231Stomach Neoplasms · China | 1 | Completed | Dec 3, 2021 | 33 |
| NCT04109456Melanoma · United States, Australia | 1 | Completed | Dec 20, 2024 | 51 |
How it is read
Names in the registry
- “IN10018”, 8 entries
- “BI 853520”, 2 entries
- “IN10018 in combination with PLD”, 1 entry
- “IN10018 in combination with RNK08954”, 1 entry
- “IN10018 in combination with D-1553”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 2 studies
- Neoplasms, 2 studies
- Pancreatic Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.